GE
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer | Nature communications |  | 2026 | 36 | 14 | ||
| Neural anticipation of virtual infection triggers an immune response | Nature neuroscience | | 2025 | 49 | 37 | ||
| Gliadin-reactive vitamin D-sensitive proinflammatory ILCPs are enriched in celiac patients | Cell reports | | 2022 | 249 | 239 | ||
| c-Maf enforces cytokine production and promotes memory-like responses in mouse and human type 2 innate lymphoid cells | EMBO journal | | 2022 | 385 | 505 | ||
| PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions | Nature Communications | | 2021 | 359 | 288 | ||
| Healthy and patient type 2 innate lymphoid cells are differently affected by in vitro culture conditions | Journal of Asthma and Allergy | | 2021 | 248 | 91 | ||
| Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer | Science Advances | | 2021 | 498 | 406 | ||
| Human primed ILCPs support endothelial activation through NF-κB signaling | eLife | | 2021 | 357 | 225 | ||
| Distinct and shared gene expression for human innate versus adaptive helper lymphoid cells | Journal of Leukocyte Biology | | 2020 | 414 | 301 | ||
| Immunosuppressive mediators impair proinflammatory innate lymphoid cell function in human malignant melanoma | Cancer Immunology Research |  | 2020 | 630 | 4 | ||
| ILC2s: new actors in tumor immunity | Frontiers in Immunology | | 2019 | 418 | 237 | ||
| Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells | Journal for Immunotherapy of Cancer | | 2019 | 372 | 210 |
